T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
暂无分享,去创建一个
Syed Abbas Ali | Michael Wang | Michael L. Wang | M. Stetler-Stevenson | D. Stroncek | S. Feldman | J. Kochenderfer | I. Maric | R. Gress | David F Stroncek | F. Hakim | Irina Maric | Maryalice Stetler-Stevenson | V. Fellowes | James N Kochenderfer | Steven A Feldman | Jeremy J Rose | Victoria Shi | Jennifer N Brudno | Brenna G Hansen | Vicki S Fellowes | Frances T Hakim | Ronald E Gress | S. A. Ali | V. Shi | J. Rose | B. Hansen | Jennifer N. Brudno
[1] J. Crowley,et al. Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival , 2012, British journal of haematology.
[2] S. Rosenberg,et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. , 2010, Blood.
[3] M. Beksac,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[4] S. Rosenberg,et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells , 2005, The Journal of experimental medicine.
[5] W. Wilson,et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.
[6] M. Raffeld,et al. B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma , 2013, Clinical Cancer Research.
[7] Sadik H. Kassim,et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. , 2013, Blood.
[8] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[9] C. Turtle,et al. Engineered T cells for anti-cancer therapy. , 2012, Current opinion in immunology.
[10] Wentian Li,et al. A Systematic Search Into The Role Of IGHV Gene Replacement In Shaping The Immunoglobulin Repertoire Of Chronic Lymphocytic Leukemia , 2013 .
[11] S. Rosenberg,et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[13] S. Rosenberg,et al. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors , 2013, Nature Reviews Clinical Oncology.
[14] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[15] P. Schneider,et al. BAFF, APRIL and their receptors: structure, function and signaling. , 2006, Seminars in immunology.
[16] D. Focosi,et al. CD57+ T lymphocytes and functional immune deficiency , 2010, Journal of leukocyte biology.
[17] B. Harder,et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. , 2004, Blood.
[18] H. Heslop,et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. , 2007, Blood.
[19] Qing He,et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.
[20] J. E. Brewer,et al. NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma , 2015, Nature Medicine.
[21] H. Huls,et al. Driving CAR-Based T-Cell Therapy to Success , 2014, Current Hematologic Malignancy Reports.
[22] R Berger,et al. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. , 1992, The EMBO journal.
[23] C. Cruz,et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. , 2013, Blood.
[24] W. Wilson,et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.
[25] S. Forman,et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. , 2003, Blood.
[26] P. Amrolia,et al. CD19 chimeric antigen receptor T cell therapy for haematological malignancies , 2015, British journal of haematology.
[27] R. Berger,et al. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. , 1994, Nucleic acids research.
[28] Sadik H. Kassim,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] W. Wilson,et al. Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor , 2009, Journal of immunotherapy.
[30] Bingyan Wu,et al. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. , 2005, Blood.
[31] S. Larson,et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.
[32] R. North. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.
[33] E. Wherry,et al. Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.
[34] S. Gottschalk,et al. Design and development of therapies using chimeric antigen receptor‐expressing T cells , 2014, Immunological reviews.
[35] Seth M Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[36] J. Shah,et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) , 2014, Leukemia.
[37] C. Mackay,et al. B Cell-Activating Factor Belonging to the TNF Family (BAFF)-R Is the Principal BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells1 , 2004, The Journal of Immunology.
[38] N. Restifo,et al. Reassessing target antigens for adoptive T cell therapy , 2013, Nature Biotechnology.
[39] F. Sallusto,et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.
[40] T. Mark,et al. Novel Induction Regimens in Multiple Myeloma , 2015, Current Hematologic Malignancy Reports.
[41] Michel Sadelain,et al. The basic principles of chimeric antigen receptor design. , 2013, Cancer discovery.
[42] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[43] M. Grever,et al. Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study. , 1990, Investigational new drugs.
[44] G. Coukos,et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[45] A. Bagg,et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. , 2015, The New England journal of medicine.
[46] Nitin J. Karandikar,et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. , 2003, Blood.
[47] S. Grupp,et al. Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.